Two Sigma Investments’s Ovid Therapeutics OVID Stock Holding History

Two Sigma Investments’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.79M	Buy	1,256,869 +658,000	+110%	+$1.18M	﹤0.01%	2492
2025 Q4	$976K	Buy	598,869 +257,735	+76%	+$397K	﹤0.01%	2931
2025 Q3	$443K	Buy	+341,134	New	+$296K	﹤0.01%	3034
2024 Q3	–	Sell	-12,628	Closed	-$9.71K	–	3280
2024 Q2	$9.71K	Sell	12,628 -28,041	-69%	-$78K	﹤0.01%	2961
2024 Q1	$124K	Buy	+40,669	New	+$136K	﹤0.01%	2804
2021 Q3	–	Sell	-288,780	Closed	-$1.13M	–	4577
2021 Q2	$1.13M	Buy	+288,780	New	+$1.14M	﹤0.01%	2373
2021 Q1	–	Sell	-345,706	Closed	-$799K	–	4147
2020 Q4	$799K	Buy	345,706 +25,441	+8%	+$119K	﹤0.01%	2175
2020 Q3	$1.84M	Buy	+320,265	New	+$2.14M	0.01%	1348
2020 Q2	–	Sell	-31,012	Closed	-$92K	–	3371
2020 Q1	$92K	Sell	31,012 -137,590	-82%	-$464K	﹤0.01%	2857
2019 Q4	$700K	Buy	+168,602	New	+$532K	﹤0.01%	2520
2019 Q3	–	Sell	-10,352	Closed	-$19K	–	3714
2019 Q2	$19K	Sell	10,352 -32,008	-76%	-$57.2K	﹤0.01%	3260
2019 Q1	$75K	Sell	42,360 -4,903	-10%	-$12.3K	﹤0.01%	2923
2018 Q4	$114K	Buy	+47,263	New	+$216K	﹤0.01%	2798

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Two Sigma Investments's OVID Position: Q1 2026 in Review

Two Sigma Investments increased its Ovid Therapeutics (OVID) stake by 110% in Q1 2026, buying an estimated $1.18M and bringing the position to 1,256,869 shares worth $2.79M. The position accounts for ﹤0.01% of the portfolio, ranked #2492.

Two Sigma Investments first reported a position in OVID in Q4 2018 and has held it in 13 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Two Sigma Investments held 1,256,869 shares of Ovid Therapeutics worth $2.79M as of Q1 2026.
Two Sigma Investments bought 658,000 Ovid Therapeutics shares in Q1 2026, an estimated $1.18M.
Ovid Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #2492 holding.
Two Sigma Investments first reported a position in Ovid Therapeutics in Q4 2018 and has held it in 13 quarters since.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.